Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H30O11 |
Molecular Weight | 494.4884 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C[C@@]1(O)[C@H](O)C[C@]2(C)OC(=O)\C=C\C4=CC=CC=C4
InChI
InChIKey=KVRQGMOSZKPBNS-FMHLWDFHSA-N
InChI=1S/C24H30O11/c1-23(35-16(27)8-7-13-5-3-2-4-6-13)11-15(26)24(31)9-10-32-22(20(23)24)34-21-19(30)18(29)17(28)14(12-25)33-21/h2-10,14-15,17-22,25-26,28-31H,11-12H2,1H3/b8-7+/t14-,15-,17-,18+,19-,20-,21+,22+,23+,24-/m1/s1
Molecular Formula | C24H30O11 |
Molecular Weight | 494.4884 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 10 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.scbt.com/scbt/product/harpagoside-19210-12-9
Curator's Comment: Description was created based on several sources, including https://www.scbt.com/scbt/product/harpagoside-19210-12-9
Harpagoside is an anti-inflammatory small molecule natural product originally isolated from the Harpagophytum procumbens (Devil's Claw) root, but can be isolated from other plants such as Crophularia ningpoensis Hemsl (Figwort). Treatment of HepG2 cells with Harpagoside demonstrated suppression of NF-κB nuclear translocation and degradation of IκB-α, blocking NF-κB activation. Multiple anti-inflammatory cellular effects were correlated with this blockade, as Harpagoside was observed to inhibit the expression of inflammation-mediating enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and to reduce lipopolysaccharide-induced mRNA levels. The suppression of NF-κB activation is indicated as the mechanism beneath the anti-inflammatory effects of Harpagoside. Harpagoside is widely used as a folk remedy to treat rheumatic complaints.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16203115 |
|||
Target ID: CHEMBL4481 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16203115 |
39.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npp/devil-s-claw.html
Devil's claw has been studied for low back pain, muscle pain, and osteoarthritis using daily doses of crude tuber up to 9 g, 1 to 3 g of extract, or harpagoside 50 to 100 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16203115
Harpagoside (200uM) significantly inhibited the induction of COX-2 and iNOS mRNA and their corresponding protein expression in LPS-treated HepG2 cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:43:13 GMT 2023
by
admin
on
Fri Dec 15 19:43:13 GMT 2023
|
Record UNII |
8KGS1DC5ZU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Harpagoside
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
2048124
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
100000145924
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
SUB124742
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
5281542
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
DTXSID101032528
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
19210-12-9
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
242-881-6
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY | |||
|
8KGS1DC5ZU
Created by
admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> POSSIBLE ACTIVE CONSTITUENT ALWAYS PRESENT |
ASSAY (HPLC)
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |